Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $1,064,906.25 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 23,125 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $46.05, for a total value of $1,064,906.25. Following the transaction, the chief executive officer now owns 307,972 shares in the company, valued at $14,182,110.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, September 11th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The shares were sold at an average price of $37.50, for a total transaction of $585,937.50.
• On Wednesday, August 21st, Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock. The stock was sold at an average price of $39.76, for a total transaction of $575,366.96.

Vera Therapeutics Trading Down 4.9 %

NASDAQ:VERA opened at $43.44 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.43 and a quick ratio of 21.43. The company’s 50-day simple moving average is $38.40 and its 200 day simple moving average is $39.03. Vera Therapeutics, Inc. has a one year low of $9.24 and a one year high of $50.78. The firm has a market capitalization of $2.38 billion, a P/E ratio of -21.19 and a beta of 0.99.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). As a group, analysts forecast that Vera Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VERA. Public Employees Retirement Association of Colorado bought a new stake in Vera Therapeutics in the 2nd quarter worth about $135,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vera Therapeutics in the second quarter worth approximately $163,000. Ameritas Investment Partners Inc. raised its holdings in shares of Vera Therapeutics by 20.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares during the last quarter. Cetera Advisors LLC bought a new position in Vera Therapeutics during the first quarter valued at approximately $235,000. Finally, Quarry LP purchased a new stake in Vera Therapeutics in the second quarter worth approximately $235,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

VERA has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a report on Monday, September 23rd. JPMorgan Chase & Co. lifted their price target on shares of Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. Finally, Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Buy” and a consensus price target of $51.75.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.